文献速递肺结节与肺癌

埃克替尼对比全脑放疗治疗EGFR突变伴多发脑转移NSCLC的3期随机试验(BRAIN)

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
PubMed 文献 · Lancet Respir Med · 2017-07-19

BRAIN研究是在中国17家医院开展的多中心、开放标签、平行随机对照3期试验,入组176例EGFR突变、未接受过EGFR-TKI或放疗、伴至少3个脑转移灶的NSCLC患者,1:1随机接受埃克替尼125 mg每日三次口服或全脑放疗(30 Gy/10次)联合化疗。

要点

  • EGFR突变NSCLC伴多发脑转移患者,埃克替尼较全脑放疗联合化疗显著延长颅内PFS。
  • 埃克替尼组3级及以上不良事件8%,全脑放疗组38%。

核心结论

  • 在EGFR突变NSCLC伴多发脑转移患者中,埃克替尼较全脑放疗联合化疗显著延长颅内PFS,提示埃克替尼可能是该人群更好的首选治疗选择。

研究设计与样本

  • 多中心、开放标签、平行随机对照3期试验(BRAIN),在中国17家医院开展。
  • 入组176例EGFR突变、未接受过EGFR-TKI或放疗、伴至少3个脑转移灶的NSCLC患者,1:1随机分配至埃克替尼85例或全脑放疗91例。
  • 埃克替尼125 mg口服每日三次;全脑放疗30 Gy分10次每次3 Gy,联合同步或序贯化疗4-6周期。
  • 随机化由中国胸部肿瘤协作组采用基于网络的分配系统、Pocock and Simon最小化法,按EGFR突变状态、治疗线数、转移部位及颅内高压症状分层。
  • 主要终点为颅内PFS,在意向治疗人群(至少接受一剂研究治疗的全部参与者)中评估疗效与安全性。

主要发现

  • 3级及以上不良事件在埃克替尼组为7/85例(8%),全脑放疗组为28/73例(38%)。
  • 两组任何级别最常见不良事件均为丙氨酸氨基转移酶升高和皮疹,各约20-30%。
  • 最终分析时埃克替尼组42例(49%)、全脑放疗组37例(51%)死亡,其中78例死于疾病进展,1例全脑放疗组患者死于化疗相关血栓形成。

关键数值与推荐

  • 样本量:随机分配176例(埃克替尼85例、全脑放疗91例),全脑放疗组18例治疗前退出,73例纳入评估。
  • 埃克替尼剂量125 mg口服每日三次;全脑放疗30 Gy分10次(每次3 Gy)。
  • 3级及以上不良事件:埃克替尼组8%(7/85),全脑放疗组38%(28/73)。

临床怎么用

  • 对EGFR突变NSCLC伴至少3个脑转移灶且未接受过EGFR-TKI或放疗的患者,可考虑以埃克替尼作为一线治疗选择。
  • 埃克替尼治疗中仅颅内进展者可转为全脑放疗联合埃克替尼或化疗;仅颅外进展者可转为埃克替尼联合化疗。
  • 全脑放疗组进展者转为埃克替尼治疗;研究者判断有临床获益时埃克替尼可超进展继续使用。

局限性

  • 开放标签设计,临床医生和患者未对治疗分配设盲。
  • 全脑放疗组18例治疗前退出,仅73例纳入评估。
  • 研究在中国17家医院开展,外部推广性需谨慎判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with non-small-cell lung cancer (NSCLC) and multiple brain metastases, whole-brain irradiation (WBI) is a standard-of-care treatment, but its effects on neurocognition are complex and concerning. We compared the efficacy of an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), icotinib, versus WBI with or without chemotherapy in a phase 3 trial of patients with EGFR-mutant NSCLC and multiple brain metastases. METHODS: We did a multicentre, open-label, parallel randomised controlled trial (BRAIN) at 17 hospitals in China. Eligible participants were patients with NSCLC with EGFR mutations, who were naive to treatment with EGFR-TKIs or radiotherapy, and had at least three metastatic brain lesions. We randomly assigned participants (1:1) to either icotinib 125 mg orally (three times per day) or WBI (30 Gy in ten fractions of 3 Gy) plus concurrent or sequential chemotherapy for 4-6 cycles, until unacceptable adverse events or intracranial disease progression occurred. The randomisation was done by the Chinese Thoracic Oncology Group with a web-based allocation system applying the Pocock and Simon minimisation method; groups were stratified by EGFR gene mutation status, treatment line (first line or second line), brain metastases only versus both intracranial and extracranial metastases, and presence or absence of symptoms of intracranial hypertension. Clinicians and patients were not masked to treatment assignment, but individuals involved in the data analysis did not participate in the treatments and were thus masked to allocation. Patients receiving icotinib who had intracranial progression only were switched to WBI plus either icotinib or chemotherapy until further progression; those receiving icotinib who had extracranial progression only were switched to icotinib plus chemotherapy. Patients receiving WBI who progressed were switched to icotinib until further progression. Icotinib could be continued beyond progression if a clinical benefit was observed by the investigators (eg, an improvement in cognition or intracranial pressure). The primary endpoint was intracranial progression-free survival (PFS), defined as the time from randomisation to either intracranial disease progression or death from any cause. We assessed efficacy and safety in the intention-to-treat population (all participants who received at least one dose of study treatment), hypothesising that intracranial PFS would be 40% longer (hazard ratio [HR] 0·60) with icotinib compared with WBI. This trial is registered with ClinicalTrials.gov, number NCT01724801. FINDINGS: Between Dec 10, 2012, and June 30, 2015, we assigned 176 participants to treatment: 85 to icotinib and 91 to WBI. 18 withdrew from the WBI group before treatment, leaving 73 for assessment. Median follow-up was 16·5 months (IQR 11·5-21·5). Median intracranial PFS was 10·0 months (95% CI 5·6-14·4) with icotinib versus 4·8 months (2·4-7·2) with WBI (equating to a 44% risk reduction with icotinib for an event of intracranial disease progression or death; HR 0·56, 95% CI 0·36-0·90; p=0·014). Adverse events of grade 3 or worse were reported in seven (8%) of 85 patients in the icotinib group and 28 (38%) of 73 patients in the WBI group. Raised concentrations of alanine aminotransferase and rash were the most common adverse events of any grade in both groups, occurring in around 20-30% of each group. At the time of final analysis, 42 (49%) patients in the icotinib group and 37 (51%) in the WBI group had died. 78 of these patients died from disease progression, and one patient in the WBI group died from thrombogenesis related to chemotherapy. INTERPRETATION: In patients with EGFR-mutant NSCLC and multiple brain metastases, icotinib was associated with significantly longer intracranial PFS than WBI plus chemotherapy, indicating that icotinib might be a better first-line therapeutic option for this patient population. FUNDING: Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine, National Health and Family Planning Commission of China, Guangzhou Science and Technology Bureau, Betta Pharmaceuticals, and the Chinese Thoracic Oncology Group.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Yang JJ, Zhou C, Huang Y, et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respir Med. 2017. PMID: 28734822. doi:10.1016/S2213-2600(17)30262-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。